The most recent AACR Cancer Progress Report outlines a surge of newly approved molecularly targeted anticancer agents that broaden the reach of precision oncology across malignancies such as breast, lung, ovarian, prostate, brain and blood cancers.
In the year-long period examined for the 2026 edition, the Food and Drug Administration granted approval to 10 new molecularly targeted therapeutics and expanded the use of two previously approved targeted drugs to additional cancer types.
These agents are designed to interfere selectively with the molecular drivers and signaling routes that fuel tumor growth, offering the possibility of greater efficacy while sparing normal tissues.
The national cancer load keeps rising, with projections that more than 2.1 million new cancer cases will be identified and that over 626,000 people are expected to succumb to the disease in the United States during 2026.
A standout development was the May 2026 clearance of vepdegestrant (Veppanu) for a subset of patients whose advanced or metastatic breast cancer is estrogen-receptor positive, HER2-negative and harbors ESR1 mutations.
The expanding portfolio of targeted drugs is driving greater reliance on molecular diagnostics, with companion diagnostics that examine tumor tissue or blood to confirm the presence of the specific genetic alteration or biomarker that a drug is intended to hit.
For instance, the FDA authorized the Guardant360 CDx test to detect ESR1-mutated breast cancers, thereby qualifying patients for treatment with imlunestrant or vepdegestrant.
Lung-cancer precision therapy also grew, as approvals were issued for zongertinib (Hernexeos) and sevabertinib (Hyrnuo) targeting advanced tumors bearing particular HER2 mutations, together with sunvozertinib (Zegfrovy) for cancers that contain EGFR exon 20 insertion mutations.
Another notable addition was relacorilant (Lifyorli), a first-in-class inhibitor of glucocorticoid-receptor signaling, approved for select individuals with platinum-resistant ovarian cancer.
Nonetheless, the report points to ongoing challenges in precision oncology, such as unequal access to biomarker testing and to the matched targeted agents, as well as the emergence of resistance mechanisms that can diminish the durability of initially successful treatments.
